Structures by: Essassi E. M.
Total: 358
Prop-2-ynyl 2-oxo-1-(prop-2-ynyl)-1,2-dihydroquinoline-4-carboxylate
C16H11NO3
IUCrData (2017) 2, 7 x171072
a=7.3070(11)Å b=8.7763(13)Å c=11.2927(13)Å
α=91.059(11)° β=107.867(12)° γ=109.814(14)°
1-Chloro-3-(6-nitro-1<i>H</i>-indazol-1-yl)propan-2-ol
C10H10ClN3O3
IUCrData (2017) 2, 5 x170637
a=4.3949(4)Å b=9.9144(8)Å c=13.1376(11)Å
α=98.4810(10)° β=90.7550(10)° γ=97.3770(10)°
1-(6-Nitro-1<i>H</i>-indazol-1-yl)ethanone
C9H7N3O3
IUCrData (2017) 2, 6 x170831
a=3.89190(10)Å b=20.4831(6)Å c=11.2580(4)Å
α=90° β=92.7570(10)° γ=90°
5-Nitro-1-(prop-2-en-1-yl)-1<i>H</i>-indazole
C10H9N3O2
IUCrData (2017) 2, 7 x171091
a=6.9549(5)Å b=11.6778(9)Å c=12.2165(9)Å
α=90° β=90° γ=90°
Ethyl 1-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylate
C13H13NO3
IUCrData (2017) 2, 6 x170917
a=12.2269(4)Å b=6.7034(3)Å c=14.0817(5)Å
α=90° β=90° γ=90°
(<i>Z</i>)-2-(2-Chlorobenzylidene)-4-(prop-2-ynyl)-2<i>H</i>-1,4-benzothiazin-3(4<i>H</i>)-one
C18H12ClNOS
IUCrData (2017) 2, 6 x170889
a=13.3937(8)Å b=8.9106(4)Å c=13.3940(7)Å
α=90° β=99.765(5)° γ=90°
1-(3-Bromo-6-nitro-1<i>H</i>-indazol-1-yl)ethan-1-one
C9H6BrN3O3
IUCrData (2017) 2, 5 x170660
a=13.9863(5)Å b=7.8783(3)Å c=18.5549(7)Å
α=90° β=100.7860(10)° γ=90°
4-Benzyl-6-bromo-2-(4-chlorophenyl)-4<i>H</i>-imidazo[4,5-<i>b</i>]pyridine
C19H13BrClN3
IUCrData (2017) 2, 6 x170899
a=8.7749(7)Å b=9.9403(7)Å c=10.4475(8)Å
α=76.030(6)° β=66.511(7)° γ=85.843(6)°
1-[(1-{[(1<i>S</i>,2<i>R</i>,6<i>R</i>,8<i>R</i>,9<i>S</i>)-4,4,11,11-Tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.0^2,6^]dodecan-8-yl]methyl}-1<i>H</i>-1,2,3-triazol-4-yl)methyl]-2,3-dihydro-1<i>H</i>-indole-2,3-dione
C23H26N4O7
IUCrData (2017) 2, 5 x170670
a=25.6622(8)Å b=8.7731(3)Å c=10.3928(3)Å
α=90° β=101.8470(10)° γ=90°
2-(3-Bromo-5-nitro-1<i>H</i>-indazol-1-yl)-1-phenylethanone
C15H10BrN3O3
IUCrData (2017) 2, 4 x170559
a=13.2690(6)Å b=15.6721(7)Å c=7.2136(3)Å
α=90° β=99.029(2)° γ=90°
4-(2-Oxopropylidene)-1,3-bis(prop-2-yn-1-yl)-2,3,4,5-tetrahydro-1<i>H</i>-1,5-benzodiazepin-2-one
C18H16N2O2
IUCrData (2016) 1, 6 x161013
a=8.6905(2)Å b=9.0249(3)Å c=10.8240(3)Å
α=68.8030(10)° β=78.5200(10)° γ=72.9800(10)°
1-Methyl-5-nitro-3-phenyl-1<i>H</i>-indazole
C14H11N3O2
IUCrData (2016) 1, 6 x160961
a=33.4769(17)Å b=7.4977(3)Å c=9.7916(4)Å
α=90° β=90° γ=90°
4-[(3-Phenyl-4,5-dihydroisoxazol-5-yl)methyl]-2<i>H</i>-benzo[<i>b</i>][1,4]thiazin-3(4<i>H</i>)-one
C18H16N2O2S
IUCrData (2016) 1, 6 x161012
a=11.7526(3)Å b=10.4082(3)Å c=25.5656(7)Å
α=90° β=90° γ=90°
2-Oxo-1,2-dihydroquinoline-4-carboxylic acid monohydrate
C10H7NO3,H2O
IUCrData (2016) 1, 6 x160997
a=20.7884(8)Å b=3.72150(10)Å c=23.8849(9)Å
α=90° β=98.582(2)° γ=90°
1-(12-Bromododecyl)-5-chloroindoline-2,3-dione
C20H27BrClNO2
IUCrData (2016) 1, 6 x160971
a=8.0353(4)Å b=8.3496(5)Å c=17.1096(11)Å
α=84.491(3)° β=78.086(3)° γ=65.126(2)°
7-Bromo-2,3-bis[(prop-2-yn-1-yl)sulfanyl]pyrido[2,3-<i>b</i>]pyrazine
C13H8BrN3S2
IUCrData (2016) 1, 11 x161881
a=4.21590(10)Å b=16.7730(5)Å c=19.4656(5)Å
α=90° β=91.1490(10)° γ=90°
3-Hydroxy-4-phenyl-2,3,4,5-tetrahydro-1<i>H</i>-1,5-benzodiazepin-2-one
C15H14N2O2
IUCrData (2016) 1, 11 x161879
a=5.519(2)Å b=21.594(8)Å c=9.917(4)Å
α=90° β=90.405(5)° γ=90°
(3<i>S</i>,4<i>S</i>)-1-Benzyl-3-hydroxy-4-phenyl-2,3,4,5-tetrahydro-1<i>H</i>-1,5-benzodiazepin-2-one
C22H20N2O2
IUCrData (2016) 1, 11 x161849
a=8.9169(2)Å b=17.6360(5)Å c=11.7937(3)Å
α=90° β=109.1990(10)° γ=90°
(2<i>Z</i>)-2-Benzylidene-4-[(1-benzyl-1<i>H</i>-1,2,3-triazol-4-yl)methyl]-3,4-dihydro-2<i>H</i>-1,4-benzothiazin-3-one
C25H20N4OS
IUCrData (2016) 1, 11 x161823
a=21.8833(8)Å b=5.7007(2)Å c=16.8054(6)Å
α=90° β=100.2340(10)° γ=90°
(<i>E</i>)-4-Methoxy-3,5-dimethyl-2-[(3-nitrophenyl)ethenyl]pyridine
C16H16N2O3
IUCrData (2016) 1, 12 x161966
a=23.3174(7)Å b=8.2979(2)Å c=7.2260(2)Å
α=90° β=90.8990(10)° γ=90°
2-Methyl-3-(3-methylisoxazol-5-yl)-4-oxo-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-1-ium chloride
C13H12N3O2,Cl
IUCrData (2016) 1, 12 x161978
a=6.2796(12)Å b=9.6912(18)Å c=21.152(4)Å
α=90° β=95.294(3)° γ=90°
Ethyl 2-{6-bromo-2-phenyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-3-yl}acetate
C16H14BrN3O2
IUCrData (2016) 1, 12 x161999
a=21.1444(14)Å b=7.6970(5)Å c=21.2671(14)Å
α=90° β=118.0730(10)° γ=90°
C16H20Cl2CoN4
C16H20Cl2CoN4
New Journal of Chemistry (2020) 44, 6 2210-2221
a=10.6315(8)Å b=9.9746(5)Å c=16.8984(13)Å
α=90° β=90.076(6)° γ=90°
C16H20Cl2N4Zn
C16H20Cl2N4Zn
New Journal of Chemistry (2020) 44, 6 2210-2221
a=21.6975(12)Å b=8.4668(3)Å c=40.556(2)Å
α=90° β=102.999(4)° γ=90°
C32H42Cl4Co2N8O
C32H42Cl4Co2N8O
New Journal of Chemistry (2020) 44, 6 2210-2221
a=8.7970(15)Å b=11.744(2)Å c=19.603(4)Å
α=77.180(5)° β=82.835(6)° γ=74.748(5)°
I,C16.87H15.62NOS
I,C16.87H15.62NOS
RSC Adv. (2016) 6, 112 111472
a=7.4292(2)Å b=10.7679(2)Å c=20.5682(4)Å
α=90° β=90.0000(10)° γ=90°
I,C18H18NOS
I,C18H18NOS
RSC Adv. (2016) 6, 112 111472
a=7.7022(8)Å b=10.3394(11)Å c=11.3339(12)Å
α=97.090(4)° β=99.284(4)° γ=91.950(4)°
2-(2-Oxo-4-phenyl-2,3-dihydro-1<i>H</i>-1,5-benzodiazepin-1-yl)acetic acid
C17H14N2O3
IUCrData (2017) 2, 1 x170120
a=17.9752(8)Å b=17.4403(8)Å c=9.2472(4)Å
α=90° β=102.8920(10)° γ=90°
NA8
C15H14N2O2
Acta Crystallographica Section E Crystallographic Communications (2020) 76, 4 467
a=8.4959(2)Å b=9.6479(2)Å c=8.7619(2)Å
α=90° β=116.9210(10)° γ=90°
2-(2-Oxo-1,3-oxazolidin-3-yl)ethyl 2-[2-(2-oxo-1,3-oxazolidin-3-yl)ethoxy]quinoline-4-carboxylate
C20H21N3O7
Acta Crystallographica Section E (2021) 77, 1 28-33
a=6.0686(5)Å b=19.2791(15)Å c=16.3795(13)Å
α=90° β=94.185(4)° γ=90°
1-Ethyl-3-phenyl-1,2-dihydroquinoxalin-2-one
C16H14N2O
Acta Crystallographica Section E (2021) 77, 1 18-22
a=9.2572(9)Å b=9.0531(9)Å c=15.0557(14)Å
α=90° β=99.3290(10)° γ=90°
(<i>Z</i>)-4-Hexyl-2-(4-methylbenzylidene)-2<i>H</i>-benzo[<i>b</i>][1,4]thiazin-3(4<i>H</i>)-one
C22H25NOS
Acta Crystallographica Section E (2020) 76, 6 889-895
a=8.8581(19)Å b=9.183(2)Å c=13.021(3)Å
α=106.474(3)° β=109.398(3)° γ=93.383(3)°
2-(2,3-Dihydro-1<i>H</i>-perimidin-2-yl)phenol
C17H14N2O
Acta Crystallographica Section E (2020) 76, 6 798-802
a=9.0710(4)Å b=12.0526(7)Å c=24.6120(11)Å
α=90° β=95.999(4)° γ=90°
Hexyl 1-hexyl-2-oxo-1,2-dihydroquinoline-4-carboxylate
C22H31NO3
Acta Crystallographica Section E (2020) 76, 5 642-645
a=17.6928(7)Å b=13.2512(5)Å c=8.5916(3)Å
α=90° β=90.184(2)° γ=90°
Ethyl 2-[(2<i>Z</i>)-2-(2-chlorobenzylidene)-3-oxo-3,4-dihydro-2<i>H</i>-\ 1,4-benzothiazin-4-yl]acetate
C19H16ClNO3S
Acta Crystallographica Section E (2020) 76, 5 629-636
a=11.6882(2)Å b=9.0903(2)Å c=16.9533(3)Å
α=90° β=105.1050(10)° γ=90°
2-(2,3-Dihydro-1<i>H</i>-perimidin-2-yl)-6-methoxyphenol
C18H16N2O2
Acta Crystallographica Section E (2020) 76, 5 605-610
a=12.7245(7)Å b=9.5887(6)Å c=23.7276(14)Å
α=90° β=90° γ=90°
1-(1,3-Benzothiazol-2-yl)-3-(2-hydroxyethyl)imidazolidin-2-one
C12H13N3O2S
Acta Crystallographica Section E (2020) 76, 3 370-376
a=7.2863(2)Å b=13.9178(5)Å c=11.6156(4)Å
α=90° β=98.8660(10)° γ=90°
(2<i>Z</i>)-2-(2,4-Dichlorobenzylidene)-4-nonyl-3,4-dihydro-2<i>H</i>-1,4-benzothiazin-3-one
C24H27Cl2NOS
Acta Crystallographica Section E (2020) 76, 2 281-287
a=8.9961(3)Å b=10.3755(3)Å c=13.2565(4)Å
α=73.8570(10)° β=88.1190(10)° γ=74.1820(10)°
1-Benzyl-3-[(1-benzyl-1<i>H</i>-1,2,3-triazol-5-yl)methyl]-2,3-dihydro-1<i>H</i>-1,3-benzodiazol-2-one monohydrate
C24H21N5O,H2O
Acta Crystallographica Section E (2020) 76, 1 95-101
a=9.0872(2)Å b=21.1012(4)Å c=11.7134(2)Å
α=90° β=112.6540(10)° γ=90°
Ethyl (2<i>S</i>,3<i>R</i>)-3-(3-amino-1<i>H</i>-1,2,4-triazol-1-yl)-2-hydroxy-3-phenylpropanoate
C13H16N4O3
Acta Crystallographica Section E (2019) 75, 12 1919-1924
a=8.4766(2)Å b=9.4841(2)Å c=16.9904(3)Å
α=90° β=94.3080(10)° γ=90°
1-Methyl-3-(prop-2-yn-1-yl)-2,3-dihydro-1<i>H</i>-1,3-benzodiazol-2-one
C11H10N2O
Acta Crystallographica Section E (2019) 75, 12 1940-1946
a=7.1507(3)Å b=8.8177(4)Å c=15.4602(7)Å
α=90° β=97.914(2)° γ=90°
(2<i>Z</i>)-4-Benzyl-2-(2,4-dichlorobenzylidene)-2<i>H</i>-1,4-benzothiazin-3(4<i>H</i>)-one
C22H15Cl2NOS
Acta Crystallographica Section E (2019) 75, 11 1650-1656
a=9.0373(7)Å b=16.6798(13)Å c=12.5110(10)Å
α=90° β=95.982(2)° γ=90°
<i>N</i>-(<i>tert</i>-butyl)-2-(phenylethynyl)imidazo[1,2-<i>a</i>]pyridin-3-\ amine
C19H19N3
Acta Crystallographica Section E (2019) 75, 10 1564-1567
a=9.3492(2)Å b=16.3716(3)Å c=10.8030(2)Å
α=90° β=90° γ=90°
3,4-Dihydro-2-(2,4-dioxo-6-methylpyran-3-ylidene)-4-(4-pyridin-4-yl)-1,5-benzodiazepine
C20H17N3O3
Acta Crystallographica Section E (2019) 75, 1 94-98
a=10.509(9)Å b=7.435(6)Å c=21.367(16)Å
α=90° β=103.041(15)° γ=90°
2-(1-decyl-2-oxoindolin-3-ylidene)propanedinitrile
C21H25N3O
Acta Crystallographica Section E (2019) 75, 1 21-25
a=44.4837(12)Å b=4.72930(10)Å c=18.3432(5)Å
α=90° β=106.965(2)° γ=90°
4-Dichloromethyl-2,3-dihydro-1<i>H</i>-1,5-benzodiazepin-2-one
C10H8Cl2N2O
Acta Crystallographica Section E (2019) 75, 1 33-37
a=12.1783(6)Å b=5.7217(3)Å c=14.8258(7)Å
α=90° β=95.7400(10)° γ=90°
1-[(1-Butyl-1<i>H</i>-1,2,3-triazol-4-yl)methyl]-3-methylquinoxalin-2(1<i>H</i>)-one
C16H19N5O
Acta Crystallographica Section E (2018) 74, 12 1815-1820
a=5.3265(2)Å b=9.9946(4)Å c=14.5414(5)Å
α=103.054(2)° β=100.039(2)° γ=93.108(2)°
5-Methyl-1,2,4-triazolo[1,5-<i>a</i>]pyrimidine
C6H6N4
Acta Crystallographica Section E (2018) 74, 12 1833-1837
a=3.7910(2)Å b=18.0092(10)Å c=9.0069(5)Å
α=90° β=101.704(2)° γ=90°
1-Benzyl-3-(prop-2-yn-1-yl)-2,3-dihydro-1<i>H</i>-1,3-benzodiazol-2-one
C17H14N2O
Acta Crystallographica Section E (2018) 74, 12 1842-1846
a=8.3567(2)Å b=9.2040(2)Å c=17.7868(4)Å
α=90° β=94.5590(10)° γ=90°
3-(4-Methylphenyl)-6-nitro-1<i>H</i>-indazole
C14H11N3O3
Acta Crystallographica Section E (2018) 74, 12 1857-1861
a=14.1447(14)Å b=11.8380(12)Å c=7.4252(8)Å
α=90° β=96.681(7)° γ=90°
1-{[2-Oxo-3-(prop-1-en-2-yl)-2,3-dihydro-1<i>H</i>-1,3-benzodiazol-1-yl)methyl}-3-(prop-1-en-2-yl)-2,3-dihydro-1<i>H</i>-1,3-benzodiazol-2-one
C21H20N4O2
Acta Crystallographica Section E (2018) 74, 12 1746-1750
a=11.5244(5)Å b=8.6312(4)Å c=17.9845(8)Å
α=90° β=94.1340(10)° γ=90°
1-Methyl-4-methylsulfanyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine
C7H8N4S
Acta Crystallographica Section E (2014) 70, 12 o1281
a=7.9309(14)Å b=15.335(3)Å c=6.7158(12)Å
α=90.00° β=90.00° γ=90.00°
6,9-Dimethyl-7<i>H</i>-[1,2,4]triazolo[4,3-<i>b</i>][1,2,4]triazepin-8(9<i>H</i>)-one 0.40-hydrate
C7H9N5O,0.4(H2O)
Acta Crystallographica Section E (2015) 71, 1 o1-o2
a=11.4970(18)Å b=11.4527(18)Å c=14.867(2)Å
α=90.00° β=109.615(4)° γ=90.00°
(4<i>Z</i>)-1-Butyl-4-(2-oxopropylidene)-2,3,4,5-tetrahydro-1<i>H</i>-1,5-benzodiazepin-2-one
C16H20N2O2
Acta Crystallographica Section E (2018) 74, 11 1669-1673
a=9.1132(6)Å b=12.6676(9)Å c=12.8164(9)Å
α=91.3440(10)° β=99.5370(10)° γ=96.3400(10)°
Ethyl 2-{4-[(3-methyl-2-oxo-1,2-dihydroquinoxalin-1-yl)methyl]-1<i>H</i>-1,2,3-triazol-1-yl}acetate
C16H17N5O3
Acta Crystallographica Section E (2018) 74, 11 1648-1652
a=7.2061(15)Å b=10.237(2)Å c=10.694(2)Å
α=95.356(3)° β=92.867(3)° γ=100.291(3)°
(2<i>Z</i>)-2-(2,4-Dichlorobenzylidene)-4-[2-(2-oxo-1,3-oxazolidin-3-yl)ethyl]-3,4-dihydro-2<i>H</i>-1,4-benzothiazin-3-one
C20H16Cl2N2O3S
Acta Crystallographica Section E (2019) 75, 5 593-599
a=18.4615(8)Å b=12.8567(5)Å c=7.9251(4)Å
α=90° β=96.926(2)° γ=90°
(2<i>Z</i>)-2-(4-Fluorobenzylidene)-4-(prop-2-yn-1-yl)-3,4-dihydro-2<i>H</i>-1,4-benzothiazin-3-one
C18H12FNOS
Acta Crystallographica Section E (2019) 75, 3 372-377
a=4.0602(2)Å b=13.8983(5)Å c=14.2620(5)Å
α=117.809(2)° β=93.155(2)° γ=94.416(2)°
3-(4,4-Dimethyl-2,3,4,5-tetrahydro-1<i>H</i>-1,5-benzodiazepin-2-ylidene)-6-methyl-3,4-dihydro-2<i>H</i>-pyran-2,4-dione
C17H18N2O3
Acta Crystallographica Section E (2019) 75, 2 228-232
a=5.53730(10)Å b=24.0197(4)Å c=11.7815(3)Å
α=90° β=103.488(2)° γ=90°
<i>N</i>-{2-[(<i>E</i>)-(4-Methylbenzylidene)amino]phenyl}-2-(5-methyl-1-<i>H</i>-pyrazol-3-yl)acetamide hemihydrate
C20H20N4O,0.5(H2O)
Acta Crystallographica Section E (2019) 75, 2 154-158
a=11.546(3)Å b=12.564(3)Å c=13.172(3)Å
α=101.991(3)° β=97.535(3)° γ=99.847(3)°
Enzyl 1-benzyl-2-oxo-1,2-dihydroquinoline-4-carboxylate
C24H19NO3
Acta Crystallographica Section E (2019) 75, 7 980-983
a=5.6101(4)Å b=19.5523(11)Å c=17.2761(11)Å
α=90° β=96.969(5)° γ=90°
Ethyl 6-chloro-2-ethoxyquinoline-4-carboxylate
C14H14ClNO3
Acta Crystallographica Section E (2019) 75, 6 912-916
a=14.2634(7)Å b=16.0124(7)Å c=13.7732(6)Å
α=90° β=117.748(2)° γ=90°
3-{(2<i>Z</i>)-2-[(2,4-Dichlorophenyl)methylidene]-3-oxo-3,4-dihydro-2<i>H</i>-1,4-benzothiazin-4-yl}propanenitrile
C18H12Cl2N2OS
Acta Crystallographica Section E (2019) 75, 6 721-727
a=6.5687(6)Å b=7.9971(7)Å c=15.4939(13)Å
α=98.105(4)° β=94.316(4)° γ=95.002(4)°
3-(4-Methoxyphenyl)-1-methyl-4-phenyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine
C19H16N4O
Acta Crystallographica Section E (2019) 75, 5 638-641
a=6.5227(3)Å b=7.8979(4)Å c=30.7774(15)Å
α=90° β=95.389(2)° γ=90°
1-Nonyl-2,3-dihydro-1<i>H</i>-indole-2,3-dione
C17H23NO2
Acta Crystallographica Section E (2019) 75, 8 1140-1144
a=16.2512(4)Å b=7.6859(2)Å c=13.0989(3)Å
α=90° β=106.6400(10)° γ=90°
(<i>Z</i>)-Ethyl 2-{5-[(2-benzylidene-3-oxo-2,3-dihydrobenzo[<i>b</i>][1,4]thiazin-4-yl)methyl]-1<i>H</i>-1,2,3-triazol-1-yl}acetate
C22H20N4O3S
Acta Crystallographica Section E (2015) 71, 12 o1022-o1023
a=9.9767(6)Å b=8.7342(5)Å c=23.1027(14)Å
α=90° β=94.5080(10)° γ=90°
1,5-Diethyl-3',5'-diphenyl-1,5-dihydro-3'<i>H</i>-spiro[pyrazolo[3,4-<i>d</i>]pyrimidine-4,2'-[1,3,4]thiadiazole]
C22H22N6S
Acta Crystallographica Section E (2015) 71, 10 o769-o770
a=14.501(5)Å b=22.898(5)Å c=12.468(4)Å
α=90° β=90° γ=90°
1,5-Dibenzyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine-4(5<i>H</i>)-thione
C19H16N4S
Acta Crystallographica Section E (2015) 71, 2 o95-o96
a=4.4953(12)Å b=29.140(8)Å c=6.3889(16)Å
α=90.00° β=97.860(9)° γ=90.00°
(<i>Z</i>)-2-Benzylidene-4-methyl-2<i>H</i>-benzo[<i>b</i>][1,4]thiazin-3(4<i>H</i>)-one
C16H13NOS
Acta Crystallographica Section E (2015) 71, 11 o862-o863
a=9.1497(3)Å b=14.7052(5)Å c=10.0037(3)Å
α=90° β=97.0510(10)° γ=90°
4-Benzyl-2<i>H</i>-benzo[<i>b</i>][1,4]thiazin-3(4<i>H</i>)-one
C15H13NOS
Acta Crystallographica Section E (2015) 71, 12 o999
a=10.8711(7)Å b=5.3815(3)Å c=21.1997(13)Å
α=90° β=93.1280(10)° γ=90°
1-[(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl]-2-(thiazol-4-yl)-1<i>H</i>-benzimidazole
C16H17N3O2S
Acta Crystallographica Section E (2015) 71, 12 o951-o952
a=9.3177(5)Å b=9.3786(6)Å c=9.5418(6)Å
α=78.739(4)° β=78.777(3)° γ=73.632(3)°
(<i>Z</i>)-7,8-Dichloro-4-(2-oxopropylidene)-4,5-dihydro-1<i>H</i>-1,5-benzodiazepin-2(3<i>H</i>)-one
C12H10Cl2N2O2
Acta Crystallographica Section E (2015) 71, 12 o1059-o1060
a=7.6789(4)Å b=13.2199(6)Å c=12.4129(7)Å
α=90° β=102.561(3)° γ=90°
(<i>E</i>)-2-Benzylidene-4-[(3-phenyl-4,5-dihydroisoxazol-5-yl)methyl]-2<i>H</i>-benzo[<i>b</i>][1,4]thiazin-3(4<i>H</i>)-one
C25H20N2O2S
Acta Crystallographica Section E (2015) 71, 6 o423-o424
a=17.4463(16)Å b=5.3024(4)Å c=22.778(2)Å
α=90° β=106.370(5)° γ=90°
Triethyl 2-(5-nitro-2<i>H</i>-indazol-2-yl)propane-1,2,3-tricarboxylate
C19H23N3O8
Acta Crystallographica Section E (2015) 71, 10 o780-o781
a=13.4555(4)Å b=18.6185(6)Å c=8.5258(3)Å
α=90° β=104.6030(10)° γ=90°
5-Chloro-1,3-bis[2-(2-oxo-1,3-oxazolidin-3-yl)ethyl]-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C17H19ClN4O5
Acta Crystallographica Section E (2015) 71, 10 o735-o736
a=14.053(8)Å b=13.438(6)Å c=9.733(4)Å
α=90° β=90° γ=90°
N-Éthyl-N-[2-(3-phénylisoxazol-5-ylméthylamino)phényl]benzylacétamide
C27H27N3O2
Acta Crystallographica Section E (2002) 58, 11 o1304-o1305
a=9.8250(10)Å b=10.9990(10)Å c=12.0950(10)Å
α=91.560(10)° β=109.220(10)° γ=109.370(10)°
C24H32CL2N8Ni1O4
C24H32CL2N8Ni1O4
Acta Crystallographica Section E (2002) 58, 7 m337-m339
a=12.1520(10)Å b=19.192(2)Å c=13.7970(10)Å
α=90.0000(10)° β=95.9610(10)° γ=90.0000(10)°
C14H14N2O2
C14H14N2O2
Acta Crystallographica Section E (2001) 57, 2 o176-o177
a=9.3000(5)Å b=15.2215(5)Å c=9.7195(5)Å
α=90.0° β=117.883(2)° γ=90.0°
C11H12N2S
C11H12N2S
Acta Crystallographica Section E (2001) 57, 4 o364-o365
a=6.6159(7)Å b=8.5070(10)Å c=9.4680(10)Å
α=88.57(6)° β=72.53(9)° γ=80.89(4)°
C18H17NO4S
C18H17NO4S
Acta Crystallographica Section E (2001) 57, 4 o362-o363
a=13.6308(8)Å b=15.1336(9)Å c=16.1540(10)Å
α=90.000(4)° β=151.086(3)° γ=90.000(10)°
C12H16N2O3
C12H16N2O3
Acta Crystallographica Section E (2001) 57, 3 o205-o206
a=5.4856(4)Å b=9.9060(10)Å c=12.2270(10)Å
α=73.429(4)° β=77.443(7)° γ=78.576(7)°
2-Méthyl-3-(3-méthyl-1H-pyrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one
C13H12N4O1
Acta Crystallographica Section E (2002) 58, 4 o388-o389
a=28.400(7)Å b=5.1148(2)Å c=18.321(4)Å
α=90.000(10)° β=120.930(10)° γ=90.000(10)°
Methyl 2-oxo-2,3-dihydro-1,3-benzothiazole-3-acetate
C10H9NO3S
Acta Crystallographica Section E (2005) 61, 11 o3872-o3873
a=4.7858(3)Å b=12.4010(7)Å c=17.5319(10)Å
α=90° β=95.679(5)° γ=90°
C12H11N3O
C12H11N3O
Acta Crystallographica Section E (2001) 57, 8 o809-o810
a=9.5437(5)Å b=11.8437(6)Å c=10.1523(3)Å
α=90.0° β=113.638(3)° γ=90.0°
1-(Pyridin-2-yl)-3-méthyl-4-(1-pyridin-2-yl-3-méthyl-1H-pyrazol-5-yl) -2H-3-pyrazoline-5(1H)-one
C18H16N6O
Acta Crystallographica Section E (2001) 57, 11 o1126-o1127
a=18.297(2)Å b=7.7645(9)Å c=11.9280(8)Å
α=90.00° β=102.681(7)° γ=90.00°
Methyl (2-benzylidene-3-oxo-1,4-benzothiazin-4-yl)acetate
C18H15NO3S
Acta Crystallographica Section E (2001) 57, 6 o498-o499
a=19.0388(6)Å b=9.6511(3)Å c=20.9817(6)Å
α=90.0° β=155.4920(10)° γ=90.0°
3-Methyl-4-(7-methylthiazolo[3,2-a]pyrimidin-5-yl)-2-phenyl-1H-pyrazol-5-one dihydrate
C17H14N4OS,2H2O
Acta Crystallographica Section E (2001) 57, 6 o500-o501
a=10.0535(2)Å b=10.9029(3)Å c=15.4808(5)Å
α=90.000(10)° β=90.000(10)° γ=90.000(10)°
C12H10Cl2N2
C12H10Cl2N2
Acta Crystallographica Section C (1998) 54, 7 964-966
a=12.8011(2)Å b=9.6258(2)Å c=19.4453(2)Å
α=90° β=92.8820(10)° γ=90°
C10H12N4O2
C10H12N4O2
Acta Crystallographica Section C (1996) 52, 4 1031-1032
a=11.507(6)Å b=12.179(1)Å c=7.928(10)Å
α=90.° β=90.03(3)° γ=90.°
1-Allyl-3-(ethoxycarbonylmethylen)-2-oxo-1,2,3,4-tetrahydroquinoxaline
C15H16N2O3
Acta Crystallographica Section C (1999) 55, 4 IUC9900021
a=9.222(5)Å b=9.365(5)Å c=16.728(9)Å
α=90.00° β=104.620(10)° γ=90.00°
4-Phenyl-2-(2-pyridylmethylsulfanyl)-3<i>H</i>-1,5-benzodiazepine
C21H17N3S
Acta Crystallographica Section E (2007) 63, 7 o3306-o3306
a=14.2995(3)Å b=8.7004(2)Å c=14.3851(4)Å
α=90.00° β=103.3370(10)° γ=90.00°
4-[(3-Hydroxy-5-phenyl-1H-pyrazol-4-yl)methyl]-5-phenyl-1H-pyrazol-3(2H)-one
C19H16N4O2
Acta Crystallographica Section E (2007) 63, 5 o2554-o2556
a=9.2908(10)Å b=16.4731(15)Å c=11.0153(13)Å
α=90.00° β=106.903(8)° γ=90.00°
4,7,10-Trioxa-1,13-diazatricyclo[11.6.3.0^14,19^]icosa-14,16,18-triene- 20,22-dione
C17H22N2O5
Acta Crystallographica Section E (2007) 63, 8 o3494-o3494
a=11.786(3)Å b=8.092(2)Å c=18.062(5)Å
α=90.00° β=103.692(17)° γ=90.00°
1-Ethyl-3-methylquinoxalin-2(1<i>H</i>)-one
C11H12N2O
Acta Crystallographica Section E (2008) 64, 11 o2234
a=7.4101(6)Å b=9.1405(8)Å c=14.2960(12)Å
α=84.976(7)° β=78.717(7)° γ=88.137(7)°
Ethyl 2-(2,3-dioxoindolin-1-yl)acetate
C12H11NO4
Acta Crystallographica Section E (2007) 63, 4 o1747-o1748
a=13.6433(6)Å b=4.9505(3)Å c=16.2899(8)Å
α=90.00° β=104.246(2)° γ=90.00°
C10H9NO2S
C10H9NO2S
Acta Crystallographica Section C (2000) 56, 5 e227-e227
a=11.3840(10)Å b=10.2020(10)Å c=14.942(2)Å
α=90.00° β=146.816(6)° γ=90.00°
C8H13N3O2S
C8H13N3O2S
Acta Crystallographica Section C (2000) 56, 4 e164-e164
a=8.2300(10)Å b=15.423(2)Å c=8.4760(10)Å
α=90.00° β=113.81(3)° γ=90.00°
C14H16N2O2
C14H16N2O2
Acta Crystallographica Section C (2000) 56, 4 e165-e166
a=8.7300(10)Å b=10.0520(10)Å c=14.998(2)Å
α=90.00° β=99.360(10)° γ=90.00°
C12H12N2O5
C12H12N2O5
Acta Crystallographica Section C (2000) 56, 10 e463-e464
a=7.6475(4)Å b=9.2255(3)Å c=17.521(5)Å
α=90.000(10)° β=99.122(2)° γ=90.000(10)°
3-Allyl-1,5-dibenzyl-1,5-benzodiazepine-2,4-dione
C26H24N2O2
Acta Crystallographica Section E (2009) 65, 12 o3150
a=9.2603(4)Å b=14.0037(6)Å c=16.2249(7)Å
α=90.00° β=91.9960(10)° γ=90.00°
1,5-Dibenzyl-3-propargyl-1,5-benzodiazepine-2,4-dione
C26H22N2O2
Acta Crystallographica Section E (2009) 65, 12 o3149
a=8.8663(2)Å b=18.6771(4)Å c=12.4665(3)Å
α=90.00° β=91.1540(10)° γ=90.00°